Voloridge Investment Management
CTMX icon

Voloridge Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Voloridge Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-26,855
Closed -$301K – 1084
2019
Q2 		$301K Buy
+26,855
New +$282K 0.01% 649

Other funds holding CTMX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Voloridge Investment Management's CTMX Position: Q3 2019 in Review

Voloridge Investment Management sold out of CytomX Therapeutics (CTMX) in Q3 2019, closing a stake of 26,855 shares — an estimated $301K sold.

Voloridge Investment Management first reported a position in CTMX in Q2 2019 and held it in 1 quarter. The position peaked at $301K in Q2 2019. 113 funds tracked by Wall St. Rank hold CTMX as of Q3 2019.

  • Voloridge Investment Management reported no remaining CytomX Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Voloridge Investment Management sold 26,855 CytomX Therapeutics shares in Q3 2019, an estimated $301K.
  • Voloridge Investment Management first reported a position in CytomX Therapeutics in Q2 2019 and held it in 1 quarter.
  • Voloridge Investment Management's CytomX Therapeutics position peaked at $301K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2019.

Based on Voloridge Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.